anti-Nipah_237
| anti-Nipah_ID | anti-Nipah_237 |
| anti-Nipah Drug | Chloroquine |
| Nipah virus strain | NiV (Malaysia ) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vivo |
| Models used to test anti-Nipah activity | Syrian Hamster |
| Mode of infection to test anti-Nipah activity | Intraperitoneal |
| Viral titer to test anti-Nipah activity | 10000 TCID50 |
| Mode of Drug delivery for anti-Nipah activity | Intraperitoneal |
| Time of Drug delivery for anti-Nipah activity | Post infection (6 hour) |
| Duration of Drug delivery for anti-Nipah activity | 24 hours |
| Drug concentration used to test anti-Nipah activity | 50 mg/kg/every other day |
| Assays used to test anti-Nipah activity | Survival assay |
| anti-Nipah activity | No significant difference [Percentage survival (NA NA)] |
| Survival rate of anti-Nipah compounds | 0 |
| References | Freiberg AN, Worthy MN, Lee B, Holbrook MR. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol. 2010 Mar;91(Pt 3):765-72. doi: 10.1099/vir.0.017269-0 |
| Comments | Ribavirin delayed death from viral disease in NiV-infected hamsters by approximately 5 days, but no significant effect in HeV-infected hamsters was observed. Chloroquine did not protect hamsters when administered either individually or in combination with ribavirin, the latter indicating the lack of a favourable drug-drug interaction. |